Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update

Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) ...
Nasdaq

Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy

Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...
Seeking Alpha

Cassava Sciences Announces Expansion of Open-Label Extension Trials

Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, ...